Immune Changes Beyond Th2 Pathways During Rapid Multifood Immunotherapy enabled with Omalizumab

ImmunotherapyImmunomodulation

Synthetic immune niches for cancer immunotherapy

Nat Rev Immunol.

Weiden J, Tel J, Figdor CG

doi: 10.1038/nri.2017.89.

Immunotherapy

Cellular Immunotherapy for Haematological Malignancies: Beyond Bone Marrow Transplant

Biol Blood Marrow Transplant.

Cirillo M, Tan P, Sturm M, Cole C

doi: 10.1016/j.bbmt.2017.10.035.

Allergic DiseasesImmunotherapy

Transcriptome changes during peanut oral immunotherapy and omalizumab treatment

Pediatr Allergy Immunol

Björkander S, Merid SK, Brodin D, Brandström J, Fagerström-Billai F, van der Heiden M, Konradsen JR, Kabesch M, van Drunen CM, Golebski K, Maitland-van der Zee AH, Potočnik U, Vijverberg SJH, Nopp A, Nilsson C, Melén E

doi: 10.1111/pai.13682

Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression

JAMA Neurol.

Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL

doi: 10.1001/

Immunotherapy

Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients

J Allergy Clin Immunol

Azzano P, Paquin M, Langlois A, Morin C, Parizeault G, Lacombe-Barrios J, Samaan K, Graham F, Paradis L, Roches AD, Begin P

doi: 10.1016/j.jaci.2020.08.039

Melanoma and Skin CancerImmunotherapy

IL-2 and Beyond in Cancer Immunotherapy

J Interferon Cytokine Res.

Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP

doi: 10.1089/jir.2017.0101.

The tumour glyco-code as a novel immune checkpoint for immunotherapy

Nat Rev Immunol.2018 Mar;18(3):204-211.doi: 10.1038/nri.2018.3.

RodrÍguez E, Schetters STT, van Kooyk Y

doi: 10.1038/nri.2018.3.

Immunotherapy

Long-term immune-related adverse events after discontinuation of immunotherapy

Immunotherapy

Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M

doi: 10.2217/imt-2020-0320

Immunotherapy

Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy

J Allergy Clin Immunol

Eljaszewicz A, Ruchti F, Radzikowska U, Globinska A, Boonpiyathad T, Gschwend A, Morita H, Helbling A, Arasi S, Kahlert H, Berek N, Nandy A, Akdis M, Willers C, Moniuszko M, Akdis CA, Sokolowska M

doi: 10.1016/j.jaci.2020.08.042

Related content

Synthetic immune niches for cancer immunotherapy

Cellular Immunotherapy for Haematological Malignancies: Beyond Bone Marrow Transplant

Transcriptome changes during peanut oral immunotherapy and omalizumab treatment

Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression

Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients

IL-2 and Beyond in Cancer Immunotherapy

The tumour glyco-code as a novel immune checkpoint for immunotherapy

Long-term immune-related adverse events after discontinuation of immunotherapy

Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy